Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406232 | 1.00 | FYN (0.50) | FYNCA1CA2CA12CA7 | |
| Hydrochloric Acid SCHEMBL866127 | 0.98 | FYN (0.48) | FYNCA1CA2CA12CA7 | |
| Hydrochloric Acid SCHEMBL29405454 | 0.98 | FYN (0.48) | FYNCA1CA2CA12CA7 | |
| SCHEMBL15630255 | 0.90 | FYN (0.42) | FYNCA1CA2CA12CA7 | |
| SCHEMBL22504662 | 0.86 | MAPT (0.58) | MAPTNFKB1THPOHIF1AHSD17B10 | |
| SCHEMBL13072957 | 0.81 | FYN (0.38) | FYNDRD3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL17513822 | 0.76 | FYN (0.33) | FYNMAPTHSD17B10ALDH1A1KDM4E | |
| SCHEMBL17949696 | 0.76 | FYN (0.38) | FYNMAPTHSD17B10ALDH1A1KDM4E | |
| SCHEMBL29653964 | 0.76 | FYN (0.38) | FYNMAPTHSD17B10ALDH1A1KDM4E | |
| SCHEMBL20443999 | 0.76 | FYN (0.33) | FYNDRD3GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115636784-B | LYW-1 derivative and preparation method and application thereof | 中国药科大学 | 2024-09-20 | — | — | CN | claimed |
| WO-2023077678-A1 | SMALL MOLECULE COMPOUND TARGETING SRSF6 PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2023-05-11 | — | — | WO | claimed |
| CN-115677577-A | Small molecular compound targeting SRSF6 protein, and preparation method and application thereof | 中国药科大学 | 2023-02-03 | — | — | CN | claimed |
| CN-107531636-B | Process for preparing indacaterol or salt thereof | 正大天晴药业集团股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-3848354-A1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | Crystal Pharma, S.A.U. (ES) | 2021-07-14 | — | — | EP | claimed |
| CN-110655467-A | Preparation method of indacaterol intermediate M | 天津药业研究院有限公司 | 2020-01-07 | — | — | CN | claimed |
| CN-110183330-A | A kind of preparation method of 5,6- diethyl -2,3- dihydro -1H- indenes -2- amine hydrochlorate | 南京焕然生物科技有限公司 | 2019-08-30 | — | — | CN | claimed |
| CN-107531636-A | The preparation method of QAB-149 or its salt | 正大天晴药业集团股份有限公司 | 2018-01-02 | — | — | CN | claimed |
| EP-2897937-B1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | CRYSTAL PHARMA SAU (ES) | 2017-12-06 | — | — | EP | claimed |
| EP-3205646-A2 | INTERMEDIATES FOR THE MANUFACTURE OF (R)-5-[2- (5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL]-8-HYDROXY-(1H)-QUINOLIN-2-ONE (INDACATEROL) | Laboratorios Lesvi, S.L. (ES) | 2017-08-16 | — | — | EP | claimed |
| EP-1613599-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | Novartis AG (CH) | 2006-01-11 | — | — | EP | claimed |
| WO-2005123684-A2 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | claimed |
| EP-1599450-A1 | PROCESS FOR PREPARING 5-\"(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMIN O)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST | Novartis AG (CH) | 2005-11-30 | — | — | EP | claimed |
| US-6933410-B2 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2005-08-23 | — | — | US | claimed |
| CN-1639111-A | Process for preparing 2-aminoindan derivatives | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | claimed |
| EP-1487781-A2 | PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES | Novartis AG (CH) | 2004-12-22 | — | — | EP | claimed |
| WO-2004087668-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | claimed |
| WO-2004076422-A1 | PROCESS FOR PREPARING 5-‘(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMINO)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | claimed |
| US-20030187301-A1 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2003-10-02 | — | — | US | claimed |
| WO-2003076387-A2 | PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES | NOVARTIS AG (CH) | 2003-09-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187301-A1 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NAT1, AADAC, IDH3A | FYN 2370/4885CA1 2153/4885CA2 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.